Company Description
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.
Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Tai-Wei Ho |
Contact Details
Address: Empire State Building, 350 5th Avenue, Suite 5330 New York, New York 10118 United States | |
| Phone | (646) 600-6438 |
| Website | in8bio.com |
Stock Details
| Ticker Symbol | INAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001740279 |
| CUSIP Number | 45674E109 |
| ISIN Number | US45674E1091 |
| Employer ID | 82-5462585 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tai-Wei Ho | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Kate Rochlin Ph.D. | Chief Operating Officer |
| Dr. Trishna Goswami M.D. | Chief Medical Officer |
| Dr. Lawrence S. Lamb Ph.D. | Executive Vice President, Co-Founder and Chief Scientific Officer |
| Patrick McCall CPA | Chief Financial Officer and Secretary |
| Michael McNamara | Vice President of Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 7, 2024 | 424B5 | Filing |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |